Bio/Pharma News

Takeda Gets Approval in Japan for Entyvio Subcutaneous Injection

March 30, 2023

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

Takeda to Invest ¥‎100 Billion (US$754 Million) into New Plasma Therapy Manufacturing Facility

March 30, 2023

Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.

Roche Collaborates with Lilly to Enhance Early Diagnosis of Alzheimer’s Disease

March 30, 2023

Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel.

Moderna and Generation Bio Announce Strategic Collaboration

March 24, 2023

Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.

Curia and Corning Collaborate to Advance Biopharmaceutical Continuous-Flow Development

March 24, 2023

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.

Invitae and Deerfield Management Team Up on Novel Therapeutics for Rare Diseases

March 22, 2023

Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.

Lynparza Approved in UK as Combination Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer

March 22, 2023

The decision was based on results from the PROpel Phase III trial.

European Commission Approves Dupixent as First, Only Targeted Medicine for Children with Severe Atopic Dermatitis

March 22, 2023

This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.

Sanofi Drops Lantus US List Price by 78%, Capping Out-of-Pocket Costs at $35

March 21, 2023

Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.

BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications

March 21, 2023

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.